Last reviewed · How we verify
One dose of PCV13a vaccine
One dose of PCV13a vaccine is a Biologic drug developed by Beijing Chaoyang District Centre for Disease Control and Prevention. It is currently in Phase 1 development.
At a glance
| Generic name | One dose of PCV13a vaccine |
|---|---|
| Sponsor | Beijing Chaoyang District Centre for Disease Control and Prevention |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of Pneumococcal 13-valent Conjugate Vaccine in Healthy People Aged 2 Months and Older (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- One dose of PCV13a vaccine CI brief — competitive landscape report
- One dose of PCV13a vaccine updates RSS · CI watch RSS
- Beijing Chaoyang District Centre for Disease Control and Prevention portfolio CI
Frequently asked questions about One dose of PCV13a vaccine
What is One dose of PCV13a vaccine?
One dose of PCV13a vaccine is a Biologic drug developed by Beijing Chaoyang District Centre for Disease Control and Prevention.
Who makes One dose of PCV13a vaccine?
One dose of PCV13a vaccine is developed by Beijing Chaoyang District Centre for Disease Control and Prevention (see full Beijing Chaoyang District Centre for Disease Control and Prevention pipeline at /company/beijing-chaoyang-district-centre-for-disease-control-and-prevention).
What development phase is One dose of PCV13a vaccine in?
One dose of PCV13a vaccine is in Phase 1.